Abstract Number: 0222 • ACR Convergence 2024
The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound
Background/Purpose: There are discrepancies between physical examination and Ultrasound (US) in detecting inflammation in Rheumatoid Arthritis (RA). In this study, we aimed to understand, according…Abstract Number: 0425 • ACR Convergence 2024
Use of bDMARDs During Pregnancy After Preconceptional Counseling in Spanish Patients with Rheumatic Diseases
Background/Purpose: Current recommendations advocate maintaining pregnancy-compatible bDMARDs during pregnancy (mainly TNF inhibitors) and monitoring disease activity before conception to improve disease and pregnancy outcomes. Recently,…Abstract Number: 0531 • ACR Convergence 2024
Costs and Clinical Outcomes of the Rheumatoid Arthritis Medication Tapering Cohort
Background/Purpose: Existing American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) guidelines regarding medication tapering in patients with rheumatoid arthritis (RA)…Abstract Number: 0667 • ACR Convergence 2024
Early Introduction of Biologic Agents in Systemic Lupus Erythematosus Reduces Relapse and Glucocorticoid Maintenance Dose: A Cohort Study from the PLEAJURE J Registry
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with diverse clinical manifestations and organ involvement, posing significant challenges in its management. The emergence…Abstract Number: 0989 • ACR Convergence 2024
Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis
Background/Purpose: To estimate the relative risk of malignancy between Janus kinase inhibitors (JAKi), tumour necrosis factor-α inhibitors (TNFi) and placebo in individuals with immune-mediated inflammatory…Abstract Number: 1374 • ACR Convergence 2024
Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer
Background/Purpose: Managing inflammatory arthritis patients on biologics with a history of cancer remains a complex task in daily rheumatology practice and requires a thoughtful, individualized…Abstract Number: 1473 • ACR Convergence 2024
Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
Background/Purpose: PsA is characterized by joint and skin inflammation, and associated with debilitating symptoms of pain and fatigue.1 Previous research has shown that pain and…Abstract Number: 1716 • ACR Convergence 2024
Comparing the Risk of Severe Infections Associated with Different Classes of Biologic or Targeted Synthetic Agents for Inflammatory Arthritis: A Population-based Study
Background/Purpose: Various classes of biologic and targeted synthetic DMARDs (b/tsDMARDs) are now available for treatment of inflammatory arthritis (IA), but little information on their relative…Abstract Number: 2044 • ACR Convergence 2024
Clinical Practice Patterns, Rilonacept Appropriate Use for Recurrent Pericarditis
Background/Purpose: Pericarditis is inflammation of the pericardial sac which can be of infectious or non-infectious etiology, commonly associated with rheumatic diseases. Pericarditis is defined as…Abstract Number: 2353 • ACR Convergence 2024
Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies
Background/Purpose: In the Phase 3 DISCOVER (D)-1 and -2 studies, guselkumab (GUS; IL-23p19-subunit inhibitor) 100 mg every 4 weeks (Q4W) or Q8W significantly improved joint…Abstract Number: 2572 • ACR Convergence 2024
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…Abstract Number: 0223 • ACR Convergence 2024
A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study
Background/Purpose: In the era of several advanced therapies and an increased number of patients with psoriatic arthritis (PsA) who have been failed by multiple treatment…Abstract Number: 0434 • ACR Convergence 2024
Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review
Background/Purpose: Biosimilar and biologic (b) DMARDs have revolutionized rheumatic disease management in the recent decades. As these drugs become introduced, it is important to understand…Abstract Number: 0532 • ACR Convergence 2024
An Immune-molecular Signature Specifically Modulated by JAK Inhibitors Ex Vivo May Serve as a Predictor of Therapy Response In Vivo to These Drugs
Background/Purpose: Despite significant therapeutic advancements in rheumatoid arthritis (RA), a substantial proportion of patients (20-40%) remain unresponsive to current treatments, including targeted synthetic DMARDs. A…Abstract Number: 0669 • ACR Convergence 2024
Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multi-system autoimmune rheumatic disorder. Despite therapeutic advances, managing SLE remains challenging due to its complex pathogenesis and…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 54
- Next Page »